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ABSTRACT
Purpose: The purpose was to explore the relationships
between irinotecan disposition and allelic variants of genes
coding for adenosine triphosphate binding cassette trans-
porters and enzymes of putative relevance for irinotecan.
Experimental Design: Irinotecan was administered to 65
cancer patients as a 90-min infusion (dose, 200–350 mg/m2),
and pharmacokinetic data were obtained during the first cycle.
All patients were genotyped for variants in genes encoding
MDR1 P-glycoprotein (ABCB1), multidrug resistance-associ-
ated proteins MRP-1 (ABCC1) and MRP-2 (canalicular
multispecific organic anion transporter; ABCC2), breast can-
cer resistance protein (ABCG2), carboxylesterases (CES1,
CES2), cytochrome P450 isozymes (CYP3A4, CYP3A5), UDP
glucuronosyltransferase (UGT1A1), and a DNA-repair enzyme
(XRCC1), which was included as a nonmechanistic control.
Results: Eighteen genetic variants were found in nine
genes of putative importance for irinotecan disposition. The
homozygous T allele of the ABCB1 1236C>T polymorphism
was associated with significantly increased exposure to iri-
notecan (P  0.038) and its active metabolite SN-38 (P 
0.031). Pharmacokinetic parameters were not related to any
of the other multiple variant genotypes, possibly because of
the low allele frequency. The extent of SN-38 glucuronida-
tion was slightly impaired in homozygous variants of
UGT1A1*28, although differences were not statistically sig-
nificant (P  0.22).
Conclusions: It is concluded that genotyping for
ABCB1 1236C>T may be one of the factors assisting with
dose optimization of irinotecan chemotherapy in cancer pa-
tients. Additional investigation is required to confirm these
findings in a larger population and to assess relationships
between irinotecan disposition and the rare variant geno-
types, especially in other ethnic groups.
INTRODUCTION
The topoisomerase I inhibitor irinotecan has a major role in
the management of metastatic colorectal cancer and has been
approved either in combination with 5-fluorouracil and folinic
acid in the first line treatment setting or as monotherapy in the
second line setting (1). In clinical use, irinotecan is subject to
very substantial interindividual variability in pharmacokinetic
behavior, treatment efficacy, and the occurrence of unpredict-
able, sometimes severe toxic side effects that might be life
threatening in some patients (2). Potential causes for such var-
iability in drug effects include the pathogenesis and severity of
the disease being treated, the occurrence of unintended drug
interactions, and impairment of hepatic and renal function or
both (3, 4). Despite the potential importance of these clinical
variables in determining drug effects, it is now recognized that
inherited differences in the metabolism and excretion into the
feces and urine can have an even greater impact on the efficacy
and toxicity of drugs (5).
The metabolism of irinotecan is very complex, and in-
volves several Phase I and II metabolizing enzymes (Fig. 1). In
humans, the ester bond of irinotecan is cleaved by CESs4 to
form the primary pharmacologically active metabolite SN-38
(6), which is further conjugated by UGT isoforms to form an
inactive -glucuronic acid conjugate, SN-38G (7). Another
prominent pathway of irinotecan metabolism consists of a
CYP3A4-mediated oxidation of the bipiperidine side chain at-
tached to the core structure, which results in the formation of a
major metabolite identified as APC (8). The pharmacological
behavior of irinotecan is additionally complicated by the fact
that its elimination pathways are partially mediated by mem-
brane-localized, energy-dependent outward drug pumps that
facilitate cellular efflux mechanisms (Fig. 1). These proteins
belong to the superfamily of ABC transporters and include
MDR1 P-glycoprotein (ABCB1; Ref. 9), multidrug resistance-
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associated protein 1 (ABCC1; Ref. 10), and its homologue
multidrug resistance-associated protein 2 [also referred to as
canalicular multispecific organic anion transporter or ABCC2;
Ref. (11)], and breast cancer resistance protein [also referred to
MXR or ABCG2; Ref. (12)]. The aim of this study was to link
genetic polymorphisms in transporters and enzymes involved in
irinotecan elimination to interindividual differences in measures
of drug exposure and to provide a stronger scientific basis for
optimizing irinotecan therapy on the basis of each patient’s
genetic constitution.
PATIENTS AND METHODS
Patients and Treatment. Patients with a histologically
confirmed diagnosis of a malignant solid tumor for which there
was no effective standard regimen and irinotecan was a reason-
able treatment option were treated with a 90-min i.v. infusion of
irinotecan. The drug was given once every 3 weeks until pro-
gression of disease or dose-limiting toxicities appeared and was
given as a single agent at a dose of 350 mg/m2 or as part of a
combination chemotherapy regimen with cisplatin at doses
ranging between 200 and 300 mg/m2. All patients were treated
between January 1997 and June 2001 at the Erasmus MC-Daniel
den Hoed Cancer Center (Rotterdam, the Netherlands). Inclu-
sion criteria included the following: (a) adequate hematopoietic
function (neutrophil count, 2.0  109/liter and platelet count,
100  109/liter); and (b) normal renal and hepatic functions
(serum creatinine concentration, 135 mol/liter and/or creat-
inine CL, 60 ml/min; serum AST and ALT concentrations,
less than three times the upper limit of normal, and less than five
times the upper limit of normal in case of liver metastasis). None
of the patients received other drugs, dietary supplements or
herbal preparations known to interfere with irinotecan pharma-
cokinetics. The clinical protocols, including blood sampling for
the purpose of pharmacokinetic and pharmacogenetic analyses,
were approved by the Erasmus MC Ethics Board, and all pa-
tients provided written informed consent before study entry.
Pharmacokinetic Data Analysis. In view of the small
intrasubject variability in irinotecan pharmacokinetic parame-
ters (2), blood samples of 5 ml were only collected during the
first cycle of treatment. The sampling was performed at the
following time points: immediately before infusion; at 30 min
after the start of the infusion; 5 min before the end of infusion;
and at 10, 20, and 30 min and 1, 1.5, 2, 4, 5, 8.5, 24, 32, and 48 h
after the end of infusion. In 37 of 65 patients, additional blood
samples were taken at 56, 196 (day 8), 360 (day 15), and 500 h
(day 21) after the end of infusion. Blood samples were handled
as outlined (13), and concentrations of irinotecan, SN-38 APC,
and SN-38G were determined in all patients by reversed-phase
high-performance liquid chromatography with fluorescence de-
tection as described in detail elsewhere (14). Concentrations of
SN-38G and APC in plasma were measured in only 53 and 12
patients, respectively, because of limited sample supply that
precluded an additional analysis on the same material.
Previously developed population pharmacokinetic models
were used to predict the pharmacokinetic parameters of the
lactone and carboxylate forms of the analytes (15). The consid-
ered parameters included CL, volume of distribution in the
central compartment, and the dose-normalized accumulated
AUC. The latter parameter was simulated for irinotecan and its
metabolites in all patients from time 0 to 100 h after start of
infusion (AUC0–100 h) for a 90-min i.v. infusion and a standard
dose of 350 mg/m2. This data analysis was performed using
NONMEM version VI (S. L. Beal and L. B. Sheiner, San Fran-
cisco, CA). Metabolic ratios were calculated as the AUC ratio of
SN-38 to irinotecan (relative extent of conversion), the AUC
ratio of SN-38G to SN-38 (REG), and the AUC ratio of APC to
irinotecan (relative extent of metabolism). To allow for a com-
parative analysis with literature data (16), the REG in each
Fig. 1 Pathway of genes with a putative role in
regulating irinotecan disposition.
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individual patient was also calculated on the basis of the linear
trapezoidal-rule AUC values from time 0 to 24 h after start of
infusion, without extrapolation to infinity, with uniform weight-
ing using noncompartmental analysis in WinNonLin version 3.0
(Pharsight Corp., Mountain View, CA).
Pharmacogenetic Data Analysis. Genomic DNA was
extracted from 1 ml of whole blood or plasma using the Gentra
PureGene Blood kit (Gentra, Minneapolis, MN) and the
QIAamp DNA Blood midi kit (Qiagen, Inc., Valencia, CA),
respectively, following the manufacturers instructions, and was
reconstituted in a buffer containing 10 mM Tris (pH 7.6) and 1
mM EDTA. SNPs and other genetic variations were identified
from the literature or were mined using the publicly available
SNP databases (17).
Variations in the ABCB1 (nucleotide 1236CT,
2677GT/A, and 3435CT), ABCC1 (14008GA, 462CT,
and 34215CG), ABCC2 (156231AG), ABCG2 (623TC),
CES1 (1440AT, 1525AC), CES2 (1647CT), CYP3A4
(CYP3A4*1B, CYP3A4*2, and CYP3A4*3), CYP3A5
(CYP3A5*3C and CYP3A5*6), UGT1A1 (UGT1A1*7 and
UGT1A1*28), and XRCC1 (26304CT, 27466GA, and
28152GA) genes were analyzed by PCR-RFLP or by Pyrose-
quencing (Table 1). Variations in the XRCC1 gene were in-
cluded as negative controls. PCR for ABCB1 3435CT and
UGT1A1*28 was carried out as described previously (18, 19).
All other PCR primers were designed using Primer Express
version 1.5 (ABI, Foster City, CA), and the Pyrosequencing
primers were designed using the Pyrosequencing SNP Primer
Design Version 1.01 software.5 RFLP sites were determined
using Rebase.6 The PCR primers, conditions, and restriction
enzymes (NEB, Beverly, MA) used in the current study are
listed in Table 1. PCR was carried out using AmpliTaq Gold
PCR master mix (ABI), 5 pmol of each primer, and 10–50 ng of
DNA isolated from whole blood or DNA from 1 l of undiluted
plasma. Pyrosequencing was carried out as previously described
(20) using the Pyrosequencing AB PSQ96 instrument and soft-
ware (Uppsala, Sweden). RFLP results were analyzed by elec-
trophoresis using 4% agarose (Promega Corporation, Madison,
WI). The genotype was called variant if it differed from the
Refseq consensus sequence for the SNP position.7 Genotype
frequency analysis of Hardy-Weinberg equilibrium was carried
out using Clump version 1.9 (21). Linkage disequilibrium be-
tween different pairs of SNPs was determined in terms of the
classical statistic D. The absolute value for D (D) of 1
denotes complete linkage disequilibrium, whereas a value of 0
denotes complete linkage equilibrium (22).
Statistical Considerations. All pharmacokinetic data are
presented as mean values  SD, unless stated otherwise. To
relate pharmacokinetic parameters with each polymorphism, a
nonparametrical Kruskal-Wallis test was used after a logarith-
mic transformation for data with a skewed distribution. These
statistical calculations were performed using SPSS version 9.0
(Paris, France) with an a priori cutoff of P  0.05. To relate
REG with the UGT1A1*28 polymorphism, a nonparametric-
trend analysis was conducted using Stata version 7.0 (Stata
Corp., College Station, TX), as described previously (16).
RESULTS
Patients and Pharmacokinetics. A total of 65 adult
cancer patients (32 males and 33 females) with a median age of
53 years was enrolled onto this study (Table 2). The majority of
patients was European Caucasian, the most prominent disease
type was a gastrointestinal malignancy, and 62 of 65 individuals
received single agent irinotecan (51 at a dose level of 350
mg/m2). The observed plasma concentration-time profiles of
irinotecan and its metabolites SN-38, SN-38G, and APC were
well predicted by previously defined NONMEM models (15), as
indicated by goodness-of-fit plots (data not shown). The indi-
vidual and mean pharmacokinetic parameters of irinotecan and
its metabolites are consistent with previous findings from pa-
tients on a similar regimen (2), showing extensive glucuronida-
tion of SN-38 with wide interindividual variability (Table 3). All
AUC ratios found in this group of patients were highly variable,
with up to 6-, 22-, and 15-fold difference between the lowest
and highest values for relative extent of conversion, REG, and
relative extent of metabolism, respectively (Table 3).
Genotyping. Seventeen SNPs and 1 dinucleotide repeat
were analyzed in nine genes of putative relevance for irinotecan
disposition (Fig. 1), and 3 SNPs in one gene likely to act
downstream of topoisomerase I inhibition (i.e., XRCC1; Ref.
23). XRCC1 was included as a control gene of unlikely signif-
5 Internet address: http://www.pyrosequencing.com.
6 Internet address: http://rebase.neb.com.
7 Internet address: http://www.ncbi.nlm.nih.gov/LocusLink/refseq.html.
Table 2 Patient demographics
No. of
patients
Median
(range)
Total no. entered (males/females) 65 (32:33)
Age (yr) 53 (34–75)
Body surface area (m2) 1.86 (1.29–2.36)
Performance score 1 (0–1)
Ethnicity
European Caucasian 63
Asian 2
Tumor types
Gastrointestinal 49
(Adeno-) carcinoma of
unknown primary
7
Miscellaneous 9a
Clinical chemistry
AST/ALT  3  ULNb 60
AST/ALT 3 to 5  ULN 5
Bilirubin  ULN 62
Bilirubin 1 to 1.5  ULN 3
Creat  ULN/creat CL  LLN 59
Creat  135 mol/l/creat CL
 60 ml/min
6
Irinotecan dose
200–230 mg/m2 6
250–300 mg/m2 8
350 mg/m2 51
Concomitant medication
Cisplatin 3
None 62
a Pancreas (five), lung (two), cervix (two).
b ULN, upper limit of normal; Creat, creatinine; LLN, lower limit
of normal.
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icance to irinotecan disposition. In 7 of the tested SNPs (i.e.,
ABCC1 462CT, ABCC2 156231AG, ABCG2 623TC,
CES1 1440AT, CYP3A4*2, CYP3A5*6, and UGT1A1*7), no
variants were observed. In the other polymorphisms studied,
frequencies of the rarest alleles ranged from 0.01 to 0.47 (Table
4). The ABCB1 2677GT/A contains a tri-allelic SNP, with G
at nucleotide 2677 found in the wild-type sequence, and with A
or T at that position being the two possible variants. All geno-
type frequencies were found to be in Hardy-Weinberg equilib-
rium. Complete genetic linkage was not seen among polymor-
phisms from within the same gene. SNPs in the ABCB1 gene
(1236CT, 2677GT/A, and 3435CT) have been previously
described to be in linkage with each other (24). In this study,
ABCB1 3435CT and ABCB1 1236CT had a D of 0.4,
ABCB1 3435CT and ABCB1 2677GT/A had a D of 	0.5,
and ABCB1 1236CT and ABCB1 2677GT/A had a D of
	0.6. Overall, 35% linkage was observed among the 3 ABCB1
SNPs. The 26% allele frequency for UGT1A1*28, a seven copy
dinucleotide repeat polymorphism in the promotor region, was
somewhat lower than the 38–40% reported in some previous
studies (25).
Genotype-Phenotype Associations. For the nine poly-
morphisms in five genes in which variant alleles were observed,
only one of the ABCB1 SNPs was associated with differences in
irinotecan and SN-38 levels (Table 5). The systemic exposure to
both irinotecan and SN-38, based on total drug concentrations,
was significantly higher for patients with two variant alleles in
ABCB1 1236 CT (i.e., the TT allele) when compared with the
patients with only one or no variant alleles. The mean AUC
values for irinotecan and SN-38 were 25.5 8.21 versus 19.8
6.81 gh/ml (P 
 0.038) and 889  445 versus 604  293
ngh/ml (P 
 0.031), respectively. Likewise, the metabolic CL
of the lactone form of SN-38 was significantly different among
homozygous variants of this SNP and wild-type or heterozygous
carriers (P 
 0.015; Table 5; Fig. 2). No statistically significant
association was observed among the other variants in ABC
transporters and any of the studied pharmacokinetic parameters
(Table 5).
Comparison of pharmacokinetic data in patients wild-type
versus heterozygous for CYP3A4*3 suggested that the CL of
irinotecan lactone might be reduced and that the AUC might be
increased in the heterozygotes, although these differences were
not statistically significant, presumably as a result of the small
sample size (P 
 0.059 and P 
 0.070, respectively). Statisti-
cally significant differences were also not observed in pharma-
cokinetic parameters, including REG (Table 6), among variants
in UGT1A1*28 (wild type  heterozygous variant  homozy-
gous variant, P  0.22).
DISCUSSION
The desire for better tools to individualize chemotherapy
has led to new ways of evaluating patients. The observation that
most chemotherapy agents have a high degree of variability in
drug disposition has prompted the use of genetics to try and
identify the mechanistic basis for this variation. Previous inves-
tigations have shown that pharmacogenetic testing may contrib-
ute to the individualization of drug treatment and hence may
have an increasing impact on enhanced drug safety and efficacy
(5). In this study, exploratory relationships were assessed be-
tween disposition characteristics of irinotecan and 21 allelic
variants of 10 genes coding for various ABC transporters and
drug-metabolizing enzymes in a group of 65 cancer patients.
The most relevant finding of this study was an apparent
association between the presence of the homozygous T allele of
ABCB1 1236CT (located at exon 12) and increased exposure
to both irinotecan and SN-38. This appears to be the first in vivo
observation that this allelic variant may be functionally poly-
morphic in that it alters the activity of the encoded protein in
relation to the wild-type and heterozygous sequences. ABCB1
1236CT is a synonymous cSNP located in codon 411 of the
P-glycoprotein. It is unlikely that this variation directly affects
the expression of P-glycoprotein. However, it may have an
indirect effect such as altering RNA stability. A comprehensive
analysis of all DNA variations in this gene is warranted to
uncover the basis of the association between P-glycoprotein and
irinotecan and SN-38 exposure.
Previously, Hoffmeyer et al. (26) found an association
between ABCB1 3435CT at exon 26 and increased exposure
to the P-glycoprotein substrate drug digoxin after oral adminis-
tration. Although this SNP is also a silent polymorphism, intes-
tinal P-glycoprotein expression was significantly decreased,
leading to increased absorption of the drug. More recently, a
study was published that confirmed the functional importance of
the ABCB1 3435CT polymorphism, although in this case, the
variant allele was associated with lower plasma concentrations
of the oral antiretroviral drugs nelfinavir and efavirenz (27). To
explain this paradox, it was hypothesized that low levels of
P-glycoprotein expression might be compensated for by over-
expression of other ABC transporter proteins with affinity for
these antiretroviral drugs and/or the induction of CYP3A iso-
forms (27). In our study, neither the ABCB1 3435CT nor the
ABCB1 2677GT/A SNP was associated with altered plasma
concentrations of irinotecan and/or its metabolites. The latter
mutation leads to the replacement of Ala to Ser or Thr but does
not appear to result directly in an altered expression of P-
glycoprotein (28).
Table 3 Summary of pharmacokinetic parameters (n 
 65)
Parameter Mean  SD Range
Irinotecan
CL lactone (liter/h) 73.0  19.9 31.1–109
AUC lactone (gh/ml) 5.73  0.856 4.05–8.04
AUC total (gh/ml) 20.5  7.07 10.4–46.1
SN-38
CL(m)a lactone (liter/h) 1,260  690 300–3,330
AUC total (gh/ml) 0.637  0.336 0.216–1.75
SN-38G
AUC total (gh/ml)b 4.46  4.67 0.962–30.0
APC
AUC total (gh/ml)c 4.57  4.02 1.12–14.0
AUC ratios
SN-38/CPT-11 0.032  0.015 0.014–0.088
SN-38G/SN-38b 7.60  5.88 1.70–37.5
APC/CPT-11c 0.21  0.15 0.035–0.53
a CL(m), metabolic clearance.
b n 
 53.
c n
 12; fewer patients were studied because of a lack of sufficient
material for repeat analyses.
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Recent investigations indicated that the metabolism of iri-
notecan is substantially influenced by a nucleotide polymor-
phism in the TATA-box sequences of UGT1A1. This gene
encodes the enzyme UGT1A1 that is responsible for the glucu-
ronidation of several compounds, including SN-38 (7). An extra
(7th) TA-repeat [A(TA)7TAA] in one allele results in 70%
reduction in transcriptional activity compared with wild-type
UGT1A1 [A(TA)6TAA]. Inheritance of the promotor containing
[A(TA)7TAA] is one of the most common genotypes leading to
Gilbert’s syndrome (29), which is characterized by mild nonhe-
molytic, unconjugated bilirubinemia. Genetic abnormalities in
UGT1A1 are also associated with the Crigler-Najjar hepatic
syndromes with absent (type I) or reduced (type II) UGT1A1
activity (29). As such patients cannot adequately metabolize
SN-38, they might be at increased risk for severe drug-related
toxicities. Indeed, it has been suggested that screening for
Fig. 2 ABCB1 1236CT variants in relation to the metabolic CL of
SN-38 lactone. Wt, wild-type patient; Het, heterozygous variant type
patient; Var, homozygous variant type patient.
Table 4 Genotype and Allele frequencies for the studied genes
Polymorphisma Nomenclature Descriptionb
Genotype
frequenciesc Allele frequencies (95% CI)d
Wt Het Var p q r
ABCB1 1236 CT n/ae G411G 23 15 8 0.66 (0.52–0.78) 0.34 (0.22–0.48)
ABCB1 3435 CT n/a E1143E 16 35 8 0.57 (0.44–0.69) 0.43 (0.31–0.56)
ABCB1 2677 GT/A n/a A893S or T 12 23/4 13/1 0.48 (0.35–0.61) 0.47 (0.34–0.60) 0.05 (0.02–0.14)
ABCC1 14008 GA n/a intron 27 32 27 5 0.71 (0.59–0.81) 0.29 (0.19–0.41)
ABCC1 462 CT n/a P154P 65 0 0 1.00 0.00
ABCC1 34215 CG n/a intron 18 0 20 40 0.17 (0.1–0.28) 0.83 (0.72–0.90)
ABCC2 156231 AG n/a intron 3 65 0 0 1.00 0.00
ABCG2 623TC n/a F208S 63 0 0 1.00 0.00
CES1 1440 AT n/a L480F 64 0 0 1.00 0.00
CES1 1525 AC n/a N509H 60 1 0 0.99 (0.92–1) 0.01 (0–0.08)
CES2 1647 CT n/a L549L 56 1 0 0.99 (0.92–1) 0.01 (0–0.08)
CYP3A4 -392 AG CYP3A4*1B Promoter 46 3 0 0.97 (0.88–0.99) 0.03 (0.01–0.12)
CYP3A4 15713 TC CYP3A4*2 S222P 39 0 0 1.00 0.00
CYP3A4 23172 TC CYP3A4*3 M445T 62 2 0 0.98 (0.91–1) 0.02 (0–0.09)
CYP3A5 22893 GA CYP3A5*3C Splice variant 56 8 0 0.94 (0.85–0.98) 0.06 (0.02–0.15)
CYP3A5 30597 GA CYP3A5*6 Splice variant 63 0 0 1.00 0.00
UGT1A1 (TA)nf UGT1A1*28 Promoter 34 22 2 0.78 (0.66–0.87) 0.22 (0.13–0.34)
UGT1A1 1456 TG UGT1A1*7 Y486D 62 0 0 1.00 0.00
XRCC1 26304 CT n/a R194W 35 8 0 0.91 (0.79–0.96) 0.09 (0.04–0.21)
XRCC1 27466 GA n/a R280H 60 2 0 0.98 (0.91–1) 0.02 (0–0.09)
XRCC1 28152 GA n/a R399Q 25 27 5 0.68 (0.55–0.79) 0.32 (0.21–0.45)
a Number represents position in nucleotide sequence.
b Number represents amino acid codon.
c Number represents number of patients.
d Hardy-Weinberg notation was used for allele frequencies (p, q, and r).
e n/a, not available; CI, confidence intervals; Wt, Wild type patient; Het, Heterozygous variant type patient; Var, Homozygous variant type
patient.
f p 
 6 dinucleotide repeats, q 
 7 dinucleotide repeats.
Table 5 Summary of genotype-phenotype associations
Polymorphism Phenotypic consequencea Pb
ABCB1 1236CT Irinotecan total AUC increased 0.038 (46)
SN-38 total AUC increased 0.031 (46)
SN-38 lactone CL reduced 0.015 (46)
ABCB1 3435CT Irinotecan lactone AUC 0.100 (59)
ABCB1 2677GT/A Irinotecan lactone CL 0.083 (53)
ABCC1 14008GA SN-38 lactone CL 0.127 (64)
ABCC1 34215CG APC AUC 0.345 (60)
CYP3A4*1B SN-38 lactone CL 0.213 (65)
CYP3A4*3 Irinotecan lactone CL 0.059 (64)
CYP3A5*3C Irinotecan carboxylate CL 0.174 (64)
UGT1A1*28 SN-38G/SN-38 AUC ratio 0.221 (53)
a Represents the best association (lowest P) between a given poly-
morphism (wild-type versus heterozygous variant versus homozygous
variant type patients) and a change in a pharmacokinetic parameter, with
number of patients in parenthesis.
b Kruskal-Wallis test following logarithmic transformation for data
with a skewed distribution; except for ABCB1 1236 CT, no statisti-
cally significant associations were found.
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UGT1A1*28 before treatment might identify patients with lower
SN-38 glucuronidation rates and greater susceptibility to irino-
tecan-induced hematological and nonhematological toxicities
(30). Unfortunately, these results could not be confirmed in our
study, although the study settings were comparable. One reason
for this discrepancy may be found in the allele frequency of the
variant allele in our population that was clearly lower than
mentioned in literature for a normal Caucasian population (25).
However, although differences in our study among genotypes
were not statistically significant, an overall trend in reduced
SN-38 glucuronidation rate (i.e., REG) in homozygous variants
of UGT1A1*28 could be observed (Table 6), particularly in the
median values, both with pharmacokinetic data based on non-
compartmental analysis or those based on the NONMEM pop-
ulation model. Furthermore, it is particularly noteworthy that
one of the two patients with the variant UGT1A1 allele in our
study with data for REG was the only individual that experi-
enced grade 4 diarrhea in the entire cohort. Clearly, additional
investigation is required to unambiguously define the associa-
tion between genetic variation in UGT1A1 and irinotecan phar-
macokinetics and pharmacodynamics.
Novel SNPs in ABCC1, ABCG2, CES1, and CES2 were
identified and evaluated in this patient set. Because of the rapid
expansion of SNP discovery and the present lack of overlap
among the various SNP databases, it is possible that additional
functional polymorphisms in these genes are still to be described
(17). For example, recent data suggest that molecular determi-
nants of SN-38 glucuronidation and irinotecan response might
include common allelic variants of the hepatic UGT1A9
isozyme (31). This may eventually provide additional refine-
ment of the predictive strategies for irinotecan.
One might seriously question if our current findings al-
ready provide meaningful tools for medical decision making in
clinical practice. It is probably too simplistic to think that the
complex metabolism of irinotecan can be predicted by screening
for one or even a few genetic variants. Because every individual
represents a combination of transporter and drug metabolizer
phenotypes and given the many enzymes involved in irinotecan
metabolism, it is apparent that some individuals are destined to
have unusual reactions to this agent because of the coincidental
occurrence of multiple genetic defects. Furthermore, it has been
shown before that various physiological and environmental fac-
tors are also involved in the way patients react to the irinotecan
therapy (2). Besides the condition of the patient and measures of
hepatic dysfunction, the role of comedication and dietary sup-
plements should not be underestimated. For example, sedatives,
antiepileptic drugs, and some corticosteroids, which are very
commonly used among patients on chemotherapy treatment, can
induce UGT1A1 and CYP3A4 activity (32, 33). In addition,
coadministration of a wide variety of agents can result in com-
petitive inhibition of CYP3A4 activity (34), whereas recom-
mended levels of the natural product St. John’s wort signifi-
cantly induce the activity of this enzyme, resulting in altered
SN-38 concentrations in plasma (35). Therefore, the next step in
predicting the pharmacokinetic and pharmacodynamic outcome
of therapy would be by focusing on phenotyping strategies
because these combine physiological, environmental, and ge-
netic factors. Hopefully, these procedures will eventually lead
toward individualized dosing of this drug. Trials implementing
a strategy to phenotype total CYP3A expression by using the
erythromycin breath test and/or midazolam CL as surrogate
markers of enzyme activity before treatment with irinotecan are
currently ongoing.
In conclusion, individuals homozygous for the T allele of
ABCB1 1236 CT appear to have altered irinotecan plasma
concentrations in comparison with heterozygous and wild-type
patients. Although this polymorphism does not completely ex-
plain the differences in irinotecan pharmacokinetics among pa-
tients, this observation may be of relevance to achieve individ-
ualized treatment strategies with this agent. Future studies will
focus on the inclusion of genotype data as a covariate in a
population model and will assess relationships between irinote-
can disposition and the rare variant genotypes, especially in
other ethnic groups.
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